Journal
INTEGRATIVE CANCER THERAPIES
Volume 18, Issue -, Pages -Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/1534735419833795
Keywords
5-fluorouracil; immunomodulatory protein; mucositis
Categories
Funding
- Ministry of Science and Technology, Taiwan [MOST 104-2311-B-040-001, MOST 106-2632-B-040-002, MOST 106-2314-B-040-017, MOST 107-2314-B-040-016-MY2]
- Chung Shan Medical University Hospital, Taiwan [CSH-2017-C-015, CSH-2019-D-008]
Ask authors/readers for more resources
5-Fluorouracil (5-FU) is used in the treatment of head and neck cancer patients. However, adverse effects experienced such as mucositis and poor appetite may lead to interruption in chemotherapy. The aim of this study is to evaluate the efficacy of GMI, one fungal immunomodulatory protein found in Ganoderma microsporum, for mucositis induced by 5-FU in a mouse model. Mice were administered 5-FU intraperitoneally for 4 days per cycle for a total of 2 chemotherapy cycles. In addition, mice were pretreated with GMI or phosphate-buffered saline 3 days before 5-FU intraperitoneal injection and daily until day 14. On histological analysis, GMI prevented 5-FU-induced damage to the intestinal mucosa and tongue epithelium. We also demonstrated that GMI enhanced the cytotoxicity of 5-FU in 2 oral cancer cell lines, while GMI could not promote this effect in an oral normal cell. In conclusion, GMI alleviates 5-FU-induced damage and decelerates cell death in normal alimentary tract tissue.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available